C hronic hepatitis B virus (HBV) infection remains a global health issue
. During the course of chronic HBV infection, hepatitis B surface Ag (HBsAg) seroclearance indicates the suppression of viral replication, whereas the HBsAgseroconversion to anti-surface Ag Ab (anti-HBs) indicates the clearance of HBV infection.
The spontaneous annual HBsAg seroclearance rate in chronically HBV-infected patients is ∼0.45-2.38% worldwide (3) (4) (5) (6) (7) , and variation in the HLA is reportedly associated with the HBsAg seroclearance rate (8) (9) (10) . A recent report showed that chronic HBV carriers with HBsAg seroclearance tend to have higher HBV viremia than those with HBsAg seroconversion (11) . Hence HBsAg seroconversion and HBV recovery are the goals of chronic HBV infection treatment. Understanding the mechanism of spontaneous HBsAg seroconversion will facilitate future development of better strategies to achieve this goal. However, the long-term natural history of spontaneous HBsAg seroconversion and the relevant host genetic factors in HBV-infected patients remain largely unclear.
HBsAg a determinant is the main epitope of anti-HBs and is the main target of the humoral immune response during the course of HBsAg seroconversion. Our previous follow-up study indicated that alanine aminotransferase (ALT) levels .30 IU/l served as a cutoff for the immune-clearance phase in chronically HBV-infected patients (12) . Various proinflammatory and regulatory cytokines, including IFN-g, IL-10, and IL-12, have been reported to alter the clinical course of chronic HBV infection, but their roles in HBsAg seroconversion and HBV recovery are incompletely understood (13) (14) (15) (16) . In this study, we examined the natural course of spontaneous HBsAg seroconversion in chronically HBV-infected patients followed from early childhood to adulthood and the relationship between cytokine gene polymorphisms and cytokine phenotypes during chronic HBV infection. The impact of HBsAg a determinant mutants on spontaneous HBsAg seroconversion was also assessed.
Materials and Methods

Patients
From 1984 to 2014, we collected genomic DNA from the peripheral blood of 296 consensual chronically HBV-infected patients (123 young females) regularly followed up at the Department of Pediatrics of National Taiwan University Hospital. All had carried HBsAg for .6 mo during follow-up and met the criteria for chronic HBV infection.
The patients were enrolled in a long-term follow-up program from a mean age of 8.40 y (SD 3.91 y) and were followed for 23.83 y (SD 3.60 y). Among the chronic HBV-infected cohort, 191 (64.5%) were born to HBsAg + mothers, 78 (26.4%) were born to HBsAg 2 mothers, and the maternal HBsAg status was unclear in 28 (9.1%) subjects. We had a total of 7053 person-years of follow-up for this cohort. Each chronic HBV-infected patient was examined at 6-mo intervals or more frequently in cases of increased ALT levels. No antiviral agent was given during the follow-up period.
In this study, clinical phases of chronic HBV infection were defined as: ALT .30 IU/l (12); 3) post-HBeAg seroconversion phase: HBeAg 2 , antiHBe + for .6 mo, ALT ,30 IU/l; and 4) HBsAg seroconversion was defined as serum HBsAg clearance and the presence of anti-HBs Abs for .6 mo.
Chronically HBV-infected subjects observed to have HBsAg seroconverted to anti-HBs for .6 mo were defined as spontaneous HBsAg seroconversion. The remaining chronically HBV-infected subjects were defined as HBsAg nonconverters.
We enrolled 193 age-matched subjects (72 males, 121 females; 34.3 6 13.0 y) from a community HBV cross-sectional screening project in Taipei City to serve as the HBV recovery group. The subjects were HBsAg 2 , anti-HBs + , and HBV core Ab (anti-HBc)-positive were considered as recovered from either acute or chronic HBV infection. The HBV recovery group was pooled with the HBsAg seroconverters from chronically HBVinfected subjects and termed the HBV seroconversion/recovery group, for the comparison of differences between the subjects with persistent HBV infection and those who cleared the virus after acute or chronic infection.
The Institutional Review Board and Ethics Committee of the hospital approved the study protocol. All patients and/or their parents/guardians provided written informed consent.
HBV serological tests, viral load, and HBV genotyping
Serum samples were obtained during each visit for HBV marker and liver function profiles. HBV markers, including HBsAg, anti-HBs, HBeAg and anti-HBe, and anti-HBc, were assessed (Abbott Laboratories, North Chicago, IL). Quantitative HBsAg titers were checked using the Architect HBsAg QT (Abbott Laboratories). The HBV genotypes and viral load of each patient were determined using real-time PCR and melting temperature curve analysis system (17) . The serum samples of 248 (83.78%) subjects in the immune-tolerance phase before HBeAg seroconversion were available for HBV viral load determination.
DNA extraction and single nucleotide polymorphism genotyping
Genomic DNA was extracted from venous blood of each participant using the Puregene kit (Gentra Systems, Minneapolis, MN) following the manufacturer's instructions. Thirteen single nucleotide polymorphisms (SNPs) in eight cytokine genes (IL-1b, IL-2, IL-4, IL-10, IL-12b, IL-13, IL-27, and IFN-g) were identified using GenBank and a Japanese and Han Chinese SNP database. We followed the SNP genotyping procedures from our previous study (15) .
PBMC isolation and in vitro culture
Whole-blood samples were collected from 67 chronically HBV-infected subjects with spontaneous HBeAg seroconversion during the study period for PBMC isolation and in vitro study. PBMC was isolated by centrifugation on Ficoll-Hypaque density medium (Pharmacia, Milton Keynes, U.K.) and washed three times before resuspension in a culture medium of RPMI 1640, L-glutamine, penicillin, streptomycin, and 10% FCS at a density of 2 3 10 6 cells/ml in a microculture plate. PBMCs (1 3 10 6 cells/ml) were incubated in recombinant HBcAg (1 mg/ml) for the PBMC stimulation cytokine release assay. The plates were incubated in a humidified incubator with 5% CO2 at a temperature of 37˚C. The supernatant was collected on the sixth day of culture for ELISA.
ELISA determination of serum IL-10 and IL-12 levels
Sequential serum samples available for 116 (39.2%) chronically HBVinfected patients were assessed for serum cytokine levels. The sequential conditions were: 1) the immune-tolerance phase, 2) the immune-clearance phase, and 3) the post-HBeAg seroconversion phase. These serum samples were assessed for serum IL-10, IL-12p70, and IL-12p40 levels using a sensitive ELISA technique (DuoSet; R&D Systems, Minneapolis, MN). The supernatants of PBMC cultures were also assessed for IL-10, IL12p70, and IL-12p40 concentrations using the ELISA.
Furin knockdown in HepG2. HBsAg a determinant mutant analysis in serum before HBeAg seroconversion Serum samples from subjects with and without spontaneous HBsAg seroconversion before HBeAg seroconversion were collected for sequence analysis of HBsAg a determinant (aa 110-160). We followed the procedures from our previous study (18) .
Statistical analysis
The STATA (StataCorp, College Station, TX) and MedCalc (ver. 12.4.0; MedCalc Software, Ostend, Belgium) software packages were used for statistical analyses. Student t test with unequal variance or Mann-Whitney U tests was used for continuous variables to test the differences in 95% confidence interval (CI)/mean or distribution/median between the two groups. Fisher's exact test or x 2 tests were used to test differences in incidence between groups. Receiver operating characteristic (ROC) curve analysis was used to determine the cutoff. Univariate and multivariate logistic regression analysis were also used to test the odds ratio (OR), 95% CI, and p values between differing SNP genotypes. Life table analysis was also used for the cumulative spontaneous HBsAg seroconversion rate. The Tables I, II) .
The HBeAg seroconversion age in this cohort was also younger in spontaneous HBsAg seroconverters (Table I) . The ROC curve analysis yielded the HBeAg seroconversion age cutoff at 10 y for the best prediction of spontaneous HBsAg seroconversion (sensitivity 56.3%, specificity 77.5%, area under the curve 69.1%; p = 0.003). HBeAg seroconversion at ,10 y of age was associated with higher HBsAg seroconversion rate (OR 5.03; 95% CI 1.80-14.08; p = 0.002); this phenomenon was also consistent in the survival analysis (HR 5.78; p = 0.001; Fig. 2 , Supplemental Table II) .
In multivariate analysis, the occurrence of immune clearance at ,48 mo of age and HBeAg seroconversion at ,10 y of age predicted earlier HBsAg seroconversion (HRs 23.38 and 3.55; p , 0.001 and p = 0.02, respectively; Supplemental Table II ). The start of immune clearance at ,48 mo of age was a predictor of HBeAg seroconversion at ,10 y of age (OR 5.81; 95% CI 2.59-13.06; p , 0.001).
Spontaneous HBsAg seroconverters also had greater peak ALT levels during the immune-clearance phase, lower initial HBsAg titers, greater overall annual rates of decreases in HBsAg titers, lower HBV viral loads in the immune-tolerance phase, and higher HBeAg seroconversion rates (Table I ). There was no significant relationship between HBV genotypes and HBsAg seroconversion (p = 0.57).
In spontaneous HBsAg seroconverters (n = 16), the median age at which serum ALT levels reached . Subgroup analysis in subjects with HBV viral load data at immune-tolerance phase
In subjects with available HBV viral load data in the immune-tolerance phase (n = 248), those with an initial baseline HBV viral load ,8 log 10 copies/ml had a higher HBsAg seroconversion rate (OR 3.42; 95% CI 1.13-10.33; p = 0.03) in single logistic regression analysis. However, an initial HBV viral load ,8 log 10 copies/ml was not significant (OR 1.48; 95% CI 0.40-5.48; p = 0.56) in a multiple logistic regression analysis considering the start of immune clearance before 48 mo of age and HBeAg seroconversion before 10 y of age. In contrast, the start of immune clearance before 48 mo of age (OR 12.15; 95% CI 3.32-44.41; p , 0.001) and HBeAg seroconversion before 10 y of age (OR 4.38; 95% CI 1.23-15.53; p = 0.02) remained significant in the subgroup multivariate analysis.
Cytokine SNPs and HBsAg seroconversion/HBV recovery
The IL-10 SNP rs1800872, IL-12b SNP rs3212217, and IL-13 SNP rs1800925 were statistically significant with p , 0.004 after Bonferroni correction (Supplemental Table III ). The prevalence rate of IL-10 SNP rs1800872 A allele-carrying subjects in the HBV recovery group (97.4%) was greater than the HBsAg nonconverter group (90%; p = 0.002), but there was no difference compared with the HBsAg-seroconversion group (93.8%; p = 0.38). The prevalence rate of IL-12b SNP rs3212217 G allele-carrying subjects was greater in the HBV recovery group than the HBsAg nonconverter group (100% versus 77.9%; p , 0.0001), but not different from the HBsAg seroconversion group (87.5%; p . 0.004). The prevalence rate of T allele-carrying subjects at IL-13 SNP rs1800925 was also higher in the HBV recovery group (50.8%) than the HBsAg nonconverter group (29.3%; p , 0.001), but was not different from the HBsAg seroconversion group (37.5%; p = 0.31). Because the prevalence of these three SNP genotypes did not differ between the HBV recovery and HBsAg seroconversion groups, these two groups were pooled in the following analysis.
The positive predictive values of HBsAg seroconversion/HBV recovery were 97.13, 99.04, and 49.76%, respectively, for IL-10 SNP rs1800872 A allele, IL-12b SNP rs3212217 G allele, and IL-13 SNP rs1800925 T allele. The A allele of IL-10 SNP rs1800872 and G allele of IL-12b SNP rs3212217 were also the most significant predictors of spontaneous HBsAg seroconversion/HBV recovery (Table II) .
Subjects carrying the A allele at IL-10 SNP rs1800872 had greater peak ALT levels during the immune-clearance phase (207.11 6 15.89 versus 98.15 6 20.62 IU/l; p = 0.0001) and greater overall annual rates of decreases in HBsAg titers (0.09 6 0.01 versus 0.05 6 0.09 log 10 IU/ml per year; p = 0.03) than C/C genotype carriers (Table III) . Subjects with G allele at IL-12b SNP rs3212217 also had greater peak ALT levels during the immuneclearance phase than C/C genotype carriers (212.79 6 17.72 versus 140.82 6 20.34 IU/l; p = 0.009).
There was no significant relation among IL-13 SNP rs1800925 genotypes in terms of ALT levels or HBsAg titers. There were also no significant differences in the prevalence of IL-1b (rs1143634, rs1143627, rs16944), IL-2 (rs2069762), IL-4 (rs2243250), IL-10 (rs3024495, rs1800871, rs1800872, rs3024491), IL-27 (rs181206), or INF-g (rs2069727) SNPs among these three groups (p . 0.004; Supplemental Table III) .
IL-10 SNP rs1800872 and IL-12b SNP rs3212217 genotypes and serum levels
Subjects with the A-allele at IL-10 SNP rs1800872, which was associated with higher HBsAg seroconversion/HBV recovery, exhibited greater serum IL-10 levels during the course of chronic HBV infection than C/C genotype-carrying subjects (Table IV) . The ratio of IL-12p70 during the immune-clearance phase compared with the immune-tolerance phase was greater in G allele-than C/C genotype-carrying subjects (p = 0.04), indicating a more sustained proinflammatory effect in IL-12b SNP rs3212217 G allele-carrying subjects during the immuneclearance phase (Table V) . The ratio of serum IL-12p70/IL12p40 during the immune-clearance phase was also borderline greater in G allele-than C/C genotype-carrying subjects (p = 0.07), which indicated a greater proinflammatory effect in the immune-clearance phase in G allele-carrying subjects. The in vitro PBMC culture study showed that PBMCs isolated from IL-10 SNP rs1800872 A-allele carrying subjects (n = 60) secreted more IL-10 than C/C genotype-carrying subjects (n = 7; 683.45 6 117.49 versus 270.11 6 123.19 pg/ml; p = 0.02). The PBMC supernatant IL-12p70/IL-12p40 ratio was also greater in IL-12b SNP rs3212217 G allele-carrying subjects (n = 59) than C/C genotype-carrying subjects (n = 8; 1.14 6 0.13 versus 0.58 6 0.22; p = 0.04).
The knockdown of furin by small interfering RNA in HepG2.2.15 hepatoma cells suppressed the biosynthesis of HBeAg, HBsAg, and HBV viral load (Supplemental Table IV ). 
No difference in HBsAg a determinant mutant
We further analyzed the HBsAg a determinant sequence (aa 110-160) in 12 spontaneous HBsAg seroconverters and 48 age-, sex-, and follow-up period-matched HBsAg nonconverters during the immune-clearance phase in this cohort study. Ten (83.33%) of the spontaneous HBsAg seroconverters and 29 (60.42%) of the HBsAg nonconverters carried a wild-type HBsAg a determinant sequence; the difference was not significant (p = 0.19).
Discussion
In this study, we demonstrated the natural course of spontaneous HBsAg seroconversion in chronically HBV-infected patients from childhood to young adulthood. Chronically HBV-infected patients with spontaneous HBsAg seroconversion had earlier entrance into the immune-clearance phase, earlier HBeAg seroconversion, greater ALT levels during the immune-clearance phase, lower HBV viral loads during the immune-tolerance phase, lower initial HBsAg titers, and higher annual rates of decreases in HBsAg titers than those without HBsAg seroconversion. Both the A allele at IL-10 SNP rs1800872 and G allele at IL-12b SNP rs3212217 predicted greater peak ALT levels during the immune-clearance phase before HBeAg seroconversion, and both were predictors of spontaneous HBsAg seroconversion/HBV recovery. Understanding the immune mechanisms that promote early immune clearance and following earlier HBeAg seroconversion in chronically HBV-infected patients and subsequent HBsAg seroconversion may facilitate formulation of improved therapeutic policies, such as treatment age and drug design.
Up to 50-60% of residents in Taiwan born before the universal HBV vaccination program were found to be HBV recoverers/ HBsAg seroconverters [HBsAg(2), anti-HBs(+), and anti-HBc (+)], which is considerably greater than the prevalence rate of acute HBV infection (2.33/100, 000) reported by the Centers for Disease Control in Taiwan (19) . We speculate that the difference may be mainly because of spontaneous recovery from either acute or chronic HBV infection before the individuals receive the HBV marker checkups. Hence chronically HBV-infected subjects with spontaneous HBsAg seroconversion may be regarded as having recovered from acute HBV infection. Although the hepatocellular carcinoma (HCC) risk declines significantly after HBsAg seroconversion in HBV-infected patients, HBsAg seroconverters with viremia have a greater HCC risk than HBV-naive subjects (20, 21) . Thus, HBsAg seroconverters with PCR + HBV DNA and/or a history of chronic infection should receive medical attention and undergo regular HCC screening.
Evidence regarding the role of the host genetic background in different clinical outcomes of HBV infection is accumulating (9) (10) (11) (12) (13) (14) (15) (16) 22) . We found that the IL-10 SNP rs1800872 (-592A/C), IL12b SNP rs3212217 (-10993C/G), and IL-13 SNP rs1800925 (-1112C/T) predicted spontaneous HBsAg seroconversion and HBV recovery in this study. High IL-10 production genotype was shown to be associated with greater ALT levels during the immune-clearance phase and greater rate of decrease in HBsAg titer in this study, which are both key elements before spontaneous HBsAg seroconversion. A previous study of chronically HBV-infected patients reported a positive relation between serum Table IV . Relation between IL-10 rs1800872 genotype and IL-10 serum levels in chronic HBV-infected patients during the course of chronic HBV infection A/A and A/C Genotypes (n = 105) C/C Genotype (n = 11) ALT and IL-10 levels during the immune-clearance phase; this is consistent with our observation (23) . A Japanese study also showed the IL-10 high-producer genotype predicts self-limiting HBV infection (24) . IL-10 was reported to activate CTLs in the presence of IL-2, whereas IL-2 is downstream of IL-12 (16) . Our study indicates that a high IL-10 level plays a beneficial role in spontaneous HBsAg seroconverters, probably in combination with coexisting proinflammatory and regulatory cytokines. IL-12p70 is a 70-kDa heterodimer, consisting of a 40-kDa (p40) and a 35-kDa (p35) subunit. IL-12p70 is an important proinflammatory cytokine that promotes differentiation of Th1 cells, enhances NK cell cytotoxicity and activation of IFN-g pathway, and rescues the antiviral function of exhausted HBV-specific T cells (25) (26) (27) . IL-12p40 homodimer could antagonize the proinflammatory function of the IL-12p70, and a high serum IL12p70/IL-12p40 ratio reflects a shift to a proinflammatory process (28) . Carriers of the G allele of IL-12b SNP rs3212217, markers of spontaneous HBsAg-seroconversion and HBV recovery, had greater ALT levels during the immune-clearance phase, greater IL-12p70/IL-12p40 ratios, and sustained IL-12p70 levels during the immune-clearance phase in chronically HBV-infected patients. IL-12p70 is associated with both cytolytic and noncytolytic HBV suppression pathways, and has been investigated as an anti-HBV agent in clinical trials (16, 29, 30) .
In our previous study of liver tissues from chronically HBVinfected patients, the IL-10 and IL-12b expression levels positively correlated with the expression levels of IFN-g and negatively with those of furin during the immune-clearance phase with ALT elevation (16) . We further demonstrated that knockdown of furin suppressed the biosynthesis of HBeAg, HBsAg and decreased the HBV viral load in hepatoma cells. Furin was reported to be essential for the maturation of HBeAg in human hepatocytes; therefore, the suppression of furin may lead to cytosolic accumulation of HBeAg proprotein p22 (31) . Cytosolic accumulation of HBeAg proprotein p22 was also reported to decrease HBV replication because of the formation of unstable nucleocapsids (32) . We speculate that elevation of ALT during the immune-clearance phase may accompany upregulation of IL-10 and IL-12 and downregulation of furin, which results in the suppression of HBV biosynthesis.
Chronically HBV-infected subjects with spontaneous HBsAg seroconversion in this study had greater peak ALT levels during the immune-clearance phase at an extremely young age, and all had normalized serum ALT levels for a median of 4.5 y before spontaneous HBsAg seroconversion. These results further support the importance of prompt inflammatory responses, earlier entrance of immune clearance, and the transition from the cytolytic to the noncytolytic HBV inhibition pathway in the process of spontaneous HBsAg seroconversion in chronic HBV infection.
IL-13 SNP rs1800925 (-1112C/T) was also found to be associated with HBV recovery and spontaneous HBsAg seroconversion, albeit with a relatively minor effect, and was not associated with serum ALT levels in this study. The T allele of IL-13 SNP rs1800925 has been reported to enhance IL-13 promoter activity (33) . IL-13 has also recently been shown to play an important role in NK T cell-mediated responses in HBV transgenic mice (34) . Future studies should assess the role of IL-13 in HBV clearance.
In conclusion, earlier entrance into the immune-clearance phase predicts subsequent spontaneous HBeAg and then HBsAg seroconversion in chronically HBV-infected patients. The A allele of IL-10 SNP rs1800872 was associated with higher serum IL-10 levels, and the G allele of IL-12b SNP rs3212217 was associated with sustained high serum IL-12p70 levels during the immune-clearance phase of chronic HBV infection. Both were associated with higher ALT levels during the immune-clearance phase and were predictors of spontaneous HBsAg seroconversion and HBV recovery.
